Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HZN-825 in diffuse systemic sclerosis
MOH_2021-08-12_010202Phase 3Recruiting
- Sponsor
- Horizon Therapeutics
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fipaxalparant in systemic sclerosis (SSc) (3 arms), sponsored by Horizon Therapeutics. Primary endpoint: Change in percent predicted forced vital capacity at Week 52. Started Jul 2021; status: recruiting.
02
Drugs
fipaxalparant
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on MOH_2021-08-12_010202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-08-12_010202.